Genetic Variation in Efflux Transporters Influences Outcome to Methotrexate Therapy in Patients with Psoriasis

Richard B. Warren; Rhodri L. Smith; Emanuela Campalani; Stephen Eyre; Catherine Smith; Juliet N. Barker; Jane Worthington; Christopher Em Griffiths

doi:10.1038/jid.2008.16

Back

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2007

Genetic variation across the methotrexate metabolic pathway and its influence upon treatment outcomes in patients with psoriasis.

Richard B. Warren, Rhodri Smith, Emanuela Campalani, Juliet N. Barker, Catherine Smith, J Worthington, Christopher Em Griffiths

Article2009

Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms

Richard B. Warren, R.L. Smith, Emanuela Campalani, Stephen Eyre, Catherine Smith, Juliet N. Barker, Jane Worthington, Christopher Em Griffiths

Article2008

Polymorphisms predictive of outcomes of methotrexate therapy in rheumatoid arthritis are not transferable to patients with psoriasis

Richard B. Warren, Rhodri Smith, Emanuela Campalani, Catherine Smith, Juliet N. Barker, J Worthington, Christopher Em Griffiths

Article2008

Methotrexate for psoriasis in the era of biological therapy

Richard B. Warren, R.J.G. Chalmers, Christopher Em Griffiths, Alan Menter

Article2015

Methotrexate polyglutamates are associated with response to treatment in psoriasis

Catriona Maybury, Abdel Douiri, Michael Duckworth, Mónica Hernández, A.V. Anstey, David Burden, Christopher Em Griffiths, Nick J. Reynolds, Anthony D. Ormerod, Richard B. Warren, Richard Woolf, A. Marinaki, Juliet N. Barker, Catherine Smith, Bstop Study